Clarivate sees obesity drug market rising to $56.8 billion by 2033, flags next-generation therapy innovators
CLVT•Clarivate report highlights next-generation obesity therapies
Clarivate published a Companies to Watch report on next-generation obesity therapies beyond first-generation GLP-1 drugs.
- Forecast obesity-drug sales across major markets rising to $56.8 billion by 2033 from $5.5 billion in 2023.
- Report flagged seven emerging developers, highlighting oral treatments, ultra-long-acting options, muscle-preserving approaches, and non-incretin mechanisms.
- Deal activity in the sector nearly doubled between 2023 and 2024, reflecting intensifying investment in differentiated obesity technologies.
